phase 2_completion
saveMerck & Co Inc — tulisokibart (Phase II Trial Completion)
community read0 votes
Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)
Data sources
globaldata
Found something off?
same company · ±60 days · 4
- earningsMerck & Co., Inc. earningsApr 30, 2026
- phase 1 initiationMK-6050: Merck & Co Inc — MK-6050 (Phase I Trial Initiation)Apr 30, 2026
- phase 2 completionpembrolizumab: Merck & Co Inc — pembrolizumab (Phase II Trial Completion)Apr 30, 2026
- pdufa(doravirine + islatravir hydrate): Merck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)Apr 28, 2026
comments(0)
5-min edit window · permanent after that